TMEM97 regulates microglial activation and neuronal stress pathways linked to neuropathic pain and neuroinflammation in multiple sclerosis (MS). Pharmacological targeting of TMEM97 has shown neuroprotective effects in models of traumatic brain injury, Huntington’s disease and retinal ganglion cell degeneration, and may reduce pain while preserving neuronal function.